Rezolute Inc Stock

$4.29

1.18% today

Nasdaq, Feb 28, 04:48 pm CET

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Internet services

Overview Dividends Analysts Charts News Strategies

Rezolute Inc Stock price

$4.24

-1.61 27.46% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.22 4.93%

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Internet services

Key metrics

Market capitalization	$256.67m
Enterprise Value	$162.06m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	2.58
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-73.34m
Cash position	$96.54m
EPS (TTM) EPS	$-1.22
P/E forward	negative
Short interest	3.81%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Rezolute Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Rezolute Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Rezolute Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Rezolute Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.03 0.03	89% 89% -
Gross Profit	-0.03 -0.03	89% 89% -
- Selling and Administrative Expenses	16 16	31% 31% -
- Research and Development Expense	57 57	15% 15% -
EBITDA	-73 -73	18% 18% -
- Depreciation and Amortization	0.03 0.03	89% 89% -
EBIT (Operating Income) EBIT	-73 -73	17% 17% -
Net Profit	-71 -71	25% 25% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Rezolute Inc Stock News

Positive

Seeking Alpha

●

10 days ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarte...

Neutral

GlobeNewsWire

●

16 days ago

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation

Neutral

GlobeNewsWire

●

24 days ago

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses

More Rezolute Inc News

Company Profile

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Nevan Elam
Employees	59
Founded	2010
Website	www.rezolutebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now